Clinical trials: Human Blood Cell Disorders, open to volunteers
Multiple Myeloma
Human BCMA Targeted T Cells Injection（BCMA CAR-T）for Subjects With R/R MM
A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human BCMA Targeted T Cells Injection（BCMA CAR-T） Therapy for R/R MM.
- Trial name
- NCT05594797
- Testing
- Human BCMA Targeted T Cells Injection
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
HIV, Hematologic Malignancies
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
Background: People living with HIV(PLWH) are at a higher risk for cancers that may be curable with a bone marrow transplant. HIV infection itself is no longer a reason to not get a transplant, for patients who otherwise have a…
- Trial name
- NCT05470491
- Testing
- RIC, GVHD prophylaxis, allo HCT
- Where
- United States
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma, Plasma Cell Disorder
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.
- Trial name
- NCT04879043
- Testing
- HDP-101
- Where
- 24 sites in United States, Germany and 3 more
- Volunteers
- 78 people
- Sponsor
- Heidelberg Pharma AG
Splenectomy
Physiology and Pathologies Linked to Human Splenic Function : Direct and Ex-vivo Perfusion Explorations
Human splenic physiology remains poorly understood due to lack of functional exploration. However, through its ability to recognize alterations or modifications in circulating cells and to trigger an innate and adaptive response…
- Trial name
- SPLEENVIVO (NCT06418256)
- Testing
- Spleen, blood and plasma collection
- Where
- 5 sites in France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glioma, Malignant, Glioblastoma
Surgical Tissue Flap to Bypass the Blood Brain Barrier in Glioblastoma
This single center, single arm, open-label, phase 2 study will assess the safety and efficacy of a pedicled temporoparietal fascial (TPF) or pericranial flap into the resection cavity of newly diagnosed glioblastoma multifome…
- Conditions
- Glioma, Malignant, Glioblastoma, Glioblastoma Multiforme, Glioblastoma Multiforme, Adult
- Trial name
- NCT05954858
- Testing
- Tissue autograft of pedicled temporoparietal fascial (TPF) or pericranial flap to bypass the blood brain barrier (BBB)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Northwell Health
Anemia, Iron Deficiency Anemia
The Effect of Combined Iron Protocols on Perioperative Allogeneic Transfusion
The goal of this clinical trial is to learn if a combined iron supplementation regimen can reduce the need for blood transfusions in adults with iron-deficiency anemia undergoing major elective cardiac surgery.
- Conditions
- Anemia, Iron Deficiency Anemia, Perioperative, Transfusion
- Trial name
- CIPAT (NCT06012760)
- Testing
- Iron sucrose, Human Erythropoietin Injection, Vitamin C, Standard Medical Care
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hepatocellular Carcinoma, Hepatitis b Virus
A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma
The investigators will first use our previously collected serum samples and surgical/biopsied tissues from HBV-related HCC patients undergoing radiotherapy.
- Conditions
- Hepatocellular Carcinoma, Hepatitis b Virus, Radiotherapy, Biomarker
- Trial name
- NCT05752890
- Volunteers
- 95 people
- Sponsor
- National Taiwan University Hospital
Human Immunodeficiency Virus Infection (HIV)
Innate-like and NK Signatures in Chronic-Treated HIV Infection INSTINCT-HIV
Infection with the human immunodeficiency virus (HIV) is a chronic condition requiring lifelong antiretroviral therapy (ART). Despite prolonged virological control under suppressive ART, HIV persists in the form of a stable viral…
- Trial name
- INSTINCT-HIV (NCT07849933)
- Testing
- Blood test
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Skin Cancer, Non-Melanoma, Skin Cancer Melanoma
Prospective Collection of Clinical Data and Human Body Material (HBM) of Cutaneous Melanoma, Non Melanoma Patients and Healthy Controls. Biobank Huidkanker
The goal of this clinical trial is to set up a prospective, fit-for-purpose collection of human body material (HBM)-blood (serum, plasma, DNA) and tissue-and standardized clinical data of patients with cutaneous melanoma…
- Trial name
- NCT07266142
- Testing
- Collection of Human Body Material and Clinical Data
- Where
- Belgium
- Volunteers
- 7,500 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Chronic Hepatitis B
Targeting ANKRD11 Reverses HBV-Specific CD8+ T Cell Dysfunction and Tolerance
Achieving a functional cure for chronic hepatitis B (CHB) is largely hindered by the irreversible functional exhaustion and immune tolerance of hepatitis B virus (HBV)-specific CD8 positive T (CD8+ T) cells.
- Trial name
- NCT07777250
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Beijing Municipal Administration of Hospitals
Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia
An Exploratory Study of RD140 Injection in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
This is a single-center, open clinical study, divided into two phases of dose escalation and dose expansion, to observe the safety and efficacy of RD140 injection at different doses in patients with relapsed/refractory multiple…
- Trial name
- NCT06655519
- Testing
- CAR-T（RD140 injection）
- Volunteers
- 12 people
- Sponsor
- Peking University People's Hospital
Hepatocellular Carcinoma
Redirected HBV-Specific T Cells in Patients With HBV-related HCC (SAFE-T-HBV)
This is a single center, single arm and open-label study to determine the safety of mRNA modified HBV-TCR redirected T-cells and to analyze the changes in tumor microenvironment caused by these HBV-TCR redirected T-cells in…
- Trial name
- SAFE-T-HBV (NCT04745403)
- Testing
- mRNA HBV/TCR T-cells
- Where
- Singapore
- Volunteers
- 10 people
- Sponsor
- Lion TCR Pte. Ltd.
Multiple Myeloma
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to…
- Trial name
- NCT06083207
- Testing
- IBI3003
- Where
- 13 sites in Australia, China
- Volunteers
- 116 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Relapsed or Refractory Multiple Myeloma
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
This is an open-label, multicenter phase 1 clinical trial to evaluate the safety and tolerability, efficacy, and pharmacokinetics of SIM0500 in adult participants with Relapsed or Refractory Multiple Myeloma(RRMM).
- Trial name
- NCT06375044
- Testing
- SIM0500
- Where
- 16 sites in United States, China
- Volunteers
- 130 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Multiple Myeloma
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety, tolerability, and how ABBV-438 moves through the body, in…
- Trial name
- NCT07409246
- Testing
- ABBV-438
- Where
- 14 sites in United States, China and 2 more
- Volunteers
- 127 people
- Sponsor
- AbbVie
Multiple Myeloma
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or…
- Trial name
- NCT06121843
- Testing
- BMS-986393, Alnuctamab, Mezigdomide
- Where
- 19 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Multiple Myeloma, Multiple Myeloma in Relapse
Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel)
CAR-T cell therapy is an emerging treatment modality in relapsed and refractory multiple myeloma (MM). CAR-T therapy in MM relies on directing autologous T-cells to detect and clear myeloma cells expressing B-cell Maturation…
- Conditions
- Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Trial name
- NCT07200089
- Testing
- NT-I7
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Washington University School of Medicine
Relapsed/Refractory Multiple Myeloma
A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma
This study is researching an experimental drug called REGN7945 in combination with another experimental drug called linvoseltamab, (also known as REGN5458) (each individually called a "study drug" or "study drugs" when combined).
- Trial name
- COSTIMM (NCT06669247)
- Testing
- Linvoseltamab, REGN7945+Linvoseltamab
- Where
- 9 sites in Australia, United Kingdom
- Volunteers
- 186 people
- Sponsor
- Regeneron Pharmaceuticals
Adrenoleukodystrophy, Batten Disease
UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells
The primary objective of the study is to determine the safety and feasibility of intrathecal administration of DUOC-01 in patients who are undergoing standard treatment with umbilical cord blood transplant (UCBT) for inborn…
- Conditions
- Adrenoleukodystrophy, Batten Disease, Mucopolysaccharidosis II, Leukodystrophy, Globoid Cell
- Trial name
- DUOC-01 (NCT02254863)
- Testing
- DUOC-01
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Joanne Kurtzberg, MD
Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS)
Safety and Tolerability of REGN17235 in Adult Participants With Clonal Cytopenia of Undetermined Significance and Low-Risk Myelodysplastic Syndrome With SF3B1 Mutation
This study will test a study drug called REGN17235 (the "study drug") to see if it can help treat Clonal Cytopenia of Undetermined Significance (CCUS) and Low-Risk Myelodysplastic Syndrome (LR-MDS) with a specific genetic…
- Trial name
- NCT07753148
- Testing
- REGN17235
- Where
- 2 sites in Belgium
- Volunteers
- 52 people
- Sponsor
- Regeneron Pharmaceuticals